Detalles de la búsqueda
1.
Switching from intravenous to subcutaneous vedolizumab maintenance treatment in patients with inflammatory bowel disease followed by therapeutic drug monitoring.
Scand J Gastroenterol
; 58(8): 863-873, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36799155
2.
Humoral immune response to SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive medication: association to serum drug levels and disease type.
Scand J Gastroenterol
; 58(8): 874-882, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36788656
3.
First-line biologic treatment of inflammatory bowel disease during the first 12 months after diagnosis from 2010 to 2016: a Norwegian nationwide registry study.
Scand J Gastroenterol
; 56(10): 1163-1168, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34320885
4.
Frailty risk and treatment strategy in elderly-onset inflammatory bowel disease. A Norwegian nationwide population-based registry study.
Dig Liver Dis
; 2024 Mar 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38433021
5.
Subcutaneous Vedolizumab Treatment in a Real-World Inflammatory Bowel Disease Cohort Switched From Intravenous Vedolizumab: Eighteen-Month Prospective Follow-up Study.
Crohns Colitis 360
; 6(1): otae013, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38544907
6.
Therapeutic management and outcomes in inflammatory bowel diseases, 2010 to 2017 in cohorts from Denmark, Sweden and Norway.
Aliment Pharmacol Ther
; 56(6): 989-1006, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35902223
7.
Incidence and Prevalence of Inflammatory Bowel Disease in Norway and the Impact of Different Case Definitions: A Nationwide Registry Study.
Clin Epidemiol
; 13: 287-294, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33935519
Resultados
1 -
7
de 7
1
Próxima >
>>